Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
FORTEO · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| FORTEO | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Periodontal surgery | PROCEDURE | - |
| FORTEO | DRUG | parathyroid hormone; self-administration for 6 weeks |
| Placebo | DRUG | placebo; self administration for 6 weeks |
| Vitamin D and Calcium | DIETARY_SUPPLEMENT | PO, QD, for six weeks |
Inclusion Criteria: * Age range: 30 to 75 years * Sex: Male and female * Female patients must be postmenopausal (for at least 2 years), surgically sterilized or utilizing one of the following methods of birth control throughout the trial - IUD, diaphragm, Depo-Provera, Norplant, oral contraceptive ...
FORTEO is used for bone loss. It is being investigated for its effects on bone loss and periodontitis, a condition involving inflammation and infection of the gums that can damage the bone supporting teeth. The drug is being studied in a clinical trial for these conditions.
FORTEO targets the parathyroid hormone (PTH) pathway. It is a small molecule designed to impact osseous cavities, which are spaces within bone. The drug's mechanism involves modulating PTH activity to influence bone remodeling and potentially counteract bone loss.
FORTEO is developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The company is conducting clinical research to evaluate the drug's safety and efficacy for bone-related conditions.
FORTEO is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug is still in the early stages of clinical testing.
FORTEO has one completed Phase 1 clinical trial with the identifier NCT00277706. The trial, titled 'Impact of Parathyroid Hormone (PTH) on Osseous Cavity,' enrolled 40 participants in the United States. It was a randomized, double-blind, placebo-controlled study involving adults aged 30 years and older.
FORTEO is the brand name for teriparatide, a recombinant form of parathyroid hormone. The drug is being studied for its effects on bone loss and periodontitis. It is administered as a small molecule and is currently in Phase 1 clinical trials.